Company Overview - Radiopharm Theranostics Limited (NASDAQ:RADX) is a biotechnology company focused on developing treatments for conditions such as brain metastasis and prostate cancer [2]. Clinical Developments - The company is advancing its RAD 101 imaging agent and RAD 204 diagnostic compound, with RAD 101 currently in a Phase 2b clinical trial and having received FDA's Fast Track Designation [3]. - RAD 204's Phase 1 clinical trial for various cancers showed absorption similar to previous studies, indicating progress in its development [3]. - The market potential for RAD 101 is significant, with approximately 300,000 people diagnosed with cerebral metastases annually in the US [3]. Analyst Insights - B. Riley has lowered its price target for RADX shares from $15 to $13 while maintaining a Buy rating, reflecting a cautious optimism regarding the company's prospects [2].
Radiopharm (RADX) Sees Slight Pessimism From Analysts